iPSC-Derived Microglia

Introduction

Induced pluripotent stem cell (iPSC)-derived microglia represent a revolutionary breakthrough in neurodegenerative disease research, providing human cellular models that faithfully recapitulate microglial biology in health and disease. These cells are generated through directed differentiation of patient-derived or gene-edited iPSCs into microglia-like cells, offering unprecedented opportunities to study microglial pathophysiology, perform drug screening, and develop personalized therapeutic approaches. The ability to derive microglia from individuals with specific genetic backgrounds—including Alzheimer’s disease (AD) patients carrying APOE4 alleles or Parkinson’s disease (PD) patients with LRRK2 mutations—has transformed our understanding of how genetic risk factors influence microglial function and contribute to neurodegeneration. ^{1Directed differentiation of human pluripotent stem cells to microglia2017 · Stem Cell Reports · PMID 28528711Open reference}

iPSC-derived microglia have emerged as essential tools for addressing fundamental questions about neuroinflammation that cannot be answered using rodent models alone. Human microglia exhibit distinct transcriptional signatures and disease-specific phenotypes that differ substantially from their murine counterparts. By generating microglia from patients with neurodegenerative diseases, researchers can now investigate disease mechanisms in a human genetic context, identify novel therapeutic targets, and screen potential drugs for efficacy in patient-specific cellular models. This approach represents a paradigm shift from traditional drug discovery methods toward precision medicine strategies that account for individual genetic variation. ^{2A Next Generation Model for Human Microglia with Point Mutations2017 · Cell Stem Cell · PMID 29100015Open reference}

The development of robust differentiation protocols has enabled the scalable production of microglia-like cells from multiple iPSC lines, making it feasible to conduct comprehensive studies comparing microglia from different disease states and genetic backgrounds. These advances have particular relevance for understanding the role of microglia in Alzheimer’s disease, where the APOE4 allele represents the strongest genetic risk factor for late-onset disease, and in Parkinson’s disease, where microglial activation contributes to disease progression. The integration of iPSC-derived microglia with brain organoids and other advanced culture systems has further enhanced their utility for modeling complex neuroimmune interactions that underlie neurodegenerative disease pathogenesis. ^{3Development and validation of humanized microglia in the mouse2020 · Nat Neurosci · PMID 32341543Open reference}

Overview

iPSC-derived microglia are microglia generated from induced pluripotent stem cells (iPSCs), providing a human cellular model for studying microglial biology, neuroimmune interactions, and therapeutic drug screening. These cells offer significant advantages over immortalized cell lines and rodent primary microglia, enabling research into disease-specific microglial phenotypes and personalized medicine approaches. The ability to derive microglia from patients with specific genetic backgrounds—including APOE4 allele carriers for Alzheimer’s disease or LRRK2 mutation carriers for Parkinson’s disease—has transformed our understanding of how genetic risk factors influence microglial function. ^{1Directed differentiation of human pluripotent stem cells to microglia2017 · Stem Cell Reports · PMID 28528711Open reference}

iPSC-derived microglia recapitulate many key features of primary human microglia, including: ^{2A Next Generation Model for Human Microglia with Point Mutations2017 · Cell Stem Cell · PMID 29100015Open reference}

• Morphology: Ramified morphology with branching processes

• Gene expression: Expression of core microglial markers (TMEM119, P2RY12, CX3CR1)

• Function: Phagocytic activity, cytokine release, and inflammatory responses

• Brain integration: Ability to integrate into organoid and assembloid systems

The derivation of microglia from induced pluripotent stem cells represents a major technological advance that addresses long-standing challenges in microglial research. Historically, studying human microglia has been limited by the difficulty of obtaining fresh brain tissue and the ethical constraints on human brain sampling. Primary microglia derived from fetal or surgical tissue samples provide valuable but limited experimental systems, with substantial variability between donors and batches. Immortalized cell lines such as BV-2 and RAW264.7 offer convenience but exhibit fundamental differences from primary human microglia in gene expression, morphology, and functional responses. iPSC-derived microglia bridge this gap by providing a renewable, standardized, and human-relevant cellular model that can be generated from multiple individuals with defined genetic backgrounds. [ ^{4Efficient generation of microglia-like cells from human iPSCs2019 · Nat Neurosci · PMID 31451805Open reference}

Multi-Taxonomy Classification

Taxonomy Database Cross-References

Morphology & Electrophysiology

• Morphology: microglial cell (source: Cell Ontology)

  • Morphology can be inferred from Cell Ontology classification

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• Cell Ontology (CL:0000129)

• OBO Foundry (CL:0000129)

• Allen Brain Cell Atlas

• CellxGene Census

• Human Cell Atlas

• PanglaoDB

Taxonomy & Classification

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• Cell Ontology (CL:0000129)

• OBO Foundry (CL:0000129)

• Allen Brain Cell Atlas

• CellxGene Census

• PanglaoDB

Derivation Methods

Embryoid Body Differentiation

The most common approach involves:

1. iPSC maintenance: Human iPSCs cultured in defined media (mTeSR1, E8)

2. Embryoid body (EB) formation: Suspension culture with BMP4, VEGF, TGF-β

3. Mesoderm induction: CD34+ hematopoietic progenitor generation

4. Myeloid differentiation: GM-CSF, IL-3, M-CSF stimulation

5. Microglial maturation: IL-34, TGF-β, CX3CL1 supplementation

6. Purification: CD45+, CD11b+ selection

Direct Reprogramming

An alternative approach uses transcription factor-mediated conversion:

• CRISPRa: Activation of microglial transcription factors (SPI1, CUX2)

• Direct conversion: Fibroblasts to microglia-like cells

• Advantages: Faster derivation, less genomic disruption

Xenofree Protocols

Modern Good Manufacturing Practice (GMP)-compatible methods:

• Defined media: No animal-derived components

• Synthetic matrices: Recombinant vitronectin

• Scalable production: Bioreactor-based expansion

Molecular Characterization

Surface Markers

Transcriptomic Comparison

RNA-seq analyses show iPSC-microglia cluster with primary human microglia:

• Highly expressed: Homeostatic genes (CX3CR1, P2RY12, TMEM119)

• Disease-relevant: Expression of AD risk genes (TREM2, CD33, CR1)

• Functional: Phagocytic and inflammatory gene programs intact

Disease Modeling Applications

Alzheimer’s Disease

iPSC-microglia from AD patients reveal:

• Aβ phagocytosis: Patient-derived microglia show impaired Aβ clearance

• Tau propagation: Enhanced uptake and spread of tau aggregates

• Inflammatory phenotype: Elevated cytokine release (IL-1β, TNF-α)

• Lipid metabolism: Altered lipid handling in APOE4 carriers

Parkinson’s Disease

PD iPSC-microglia demonstrate:

• α-Synuclein processing: Reduced degradation of α-synuclein

• Neurotoxicity: Increased vulnerability to mitochondrial toxins

• Inflammatory responses: Exaggerated cytokine release to environmental triggers

Amyotrophic Lateral Sclerosis (ALS)

ALS patient-derived microglia:

• Motorneuron support: Reduced neuroprotective factor secretion

• Inflammatory phenotype: Hyper-active state

• TDP-43 pathology: Internalization of TDP-43 aggregates

Mechanisms of Disease in iPSC-Derived Microglia

APOE4-Mediated Dysfunction

The APOE4 allele represents the strongest genetic risk factor for late-onset Alzheimer’s disease. iPSC-derived microglia from APOE4 carriers demonstrate profound molecular and cellular alterations that recapitulate disease phenotypes. ^{5APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived microglia2018 · Nat Neurosci · PMID 29556031Open reference}

Lipid Metabolism Impairment: APOE4 microglia exhibit defective cholesterol efflux and lipid droplet accumulation. The APOE4 protein adopts a domain interaction phenotype that reduces its lipid-binding capacity, leading to intracellular lipid accumulation and foam cell formation. ^{6APOE4 iPSC-microglia display impaired lipid metabolism2022 · Cell Metab · PMID 35077933Open reference}

Inflammatory Response Amplification: APOE4 microglia show elevated baseline inflammation with increased expression of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. This hyper-inflammatory state contributes to chronic neuroinflammation and neuronal dysfunction. ^{7Inflammatory phenotypes in iPSC-microglia from AD patients2021 · J Immunol · PMID 33858962Open reference}

Synaptic Pruning Dysregulation: APOE4 microglia demonstrate enhanced synaptic elimination through complement-mediated mechanisms. Increased C1q and C3 expression leads to excessive tagging of synapses for phagocytosis, contributing to synaptic loss in AD. ^{8Human iPSC microglia show disease-associated phenotypes2021 · Nat Med · PMID 34140667Open reference}

Tau Pathology Propagation

iPSC-derived microglia facilitate the spread of tau pathology through several mechanisms: ^{2A Next Generation Model for Human Microglia with Point Mutations2017 · Cell Stem Cell · PMID 29100015Open reference}0

1. Tau uptake: Microglia internalize tau aggregates via macropinocytosis and receptor-mediated endocytosis

2. Tau processing: Internalized tau is processed through the endolysosomal system

3. Tau spreading: Microglia can release tau species in exosomes, contributing to prion-like propagation

4. Microglial activation: Tau aggregates activate microglia, creating a feed-forward inflammatory loop

Alpha-Synuclein Processing in PD

iPSC-microglia from Parkinson’s disease patients show impaired handling of α-synuclein: ^{2A Next Generation Model for Human Microglia with Point Mutations2017 · Cell Stem Cell · PMID 29100015Open reference}1

• Reduced degradation: Decreased autophagy flux leads to α-synuclein accumulation

• Exosome release: Increased exosomal secretion of α-synuclein promotes spread

• Inflammatory activation: α-Synuclein aggregates trigger NLRP3 inflammasome activation

Mitochondrial Dysfunction

AD patient-derived iPSC-microglia exhibit mitochondrial defects: ^{2A Next Generation Model for Human Microglia with Point Mutations2017 · Cell Stem Cell · PMID 29100015Open reference}2

• Reduced mitochondrial membrane potential

• Decreased ATP production

• Increased reactive oxygen species (ROS) generation

• Impaired mitophagy leading to mitochondrial accumulation

Single-Cell Transcriptomic Insights

Single-cell RNA sequencing has revealed substantial heterogeneity in iPSC-derived microglia: ^{2A Next Generation Model for Human Microglia with Point Mutations2017 · Cell Stem Cell · PMID 29100015Open reference}3

Advanced Disease Modeling Platforms

Brain Organoid Systems

iPSC-microglia integration into brain organoids provides sophisticated disease modeling: ^{2A Next Generation Model for Human Microglia with Point Mutations2017 · Cell Stem Cell · PMID 29100015Open reference}4

• Development modeling: Microglia colonize organoids during development

• Circuit formation: Enable study of neuron-microglia interactions

• Disease phenotypes: Recapitulate AD/PD pathological features

flowchart TD
    A["iPSC"] --> B["EB Formation"]
    B --> C["Mesoderm Induction"]
    C --> D["Hematopoietic Progenitors"]
    D --> E["Myeloid Differentiation"]
    E --> F["Microglial Maturation"]
    F --> G["iPSC-Derived Microglia"]

    G --> H["Disease Modeling"]
    G --> I["Drug Screening"]
    G --> J["Transplantation"]

    H --> K["AD/PD/ALS Phenotypes"]
    I --> L["High-Throughput Screening"]
    J --> M["Cell Therapy"]

    K --> N["Mechanism Studies"]
    L --> N
    N --> O["Therapeutic Targets"]

Microfluidic Models

Microfluidic chips enable precise control of microenvironment:

• BBB modeling: Study microglia transmigration across the blood-brain barrier

• Gradient systems: Model chemokine gradients in development and disease

• Drug screening: High-throughput compound testing in defined conditions

Therapeutic Target Discovery

CRISPR Screening Approaches

Recent CRISPR screens have identified novel microglial therapeutic targets: ^{2A Next Generation Model for Human Microglia with Point Mutations2017 · Cell Stem Cell · PMID 29100015Open reference}5

• TREM2 modulators: Enhance or inhibit TREM2 signaling

• Inflammatory pathway inhibitors: Target specific cytokine pathways

• Phagocytosis enhancers: Improve Aβ clearance

• Metabolic modulators: Correct lipid metabolism defects

Small Molecule Screening

iPSC-microglia enable phenotypic drug screening:

Developmental Biology Applications

Microglia in Brain Development

iPSC-derived microglia recapitulate developmental functions: ^{2A Next Generation Model for Human Microglia with Point Mutations2017 · Cell Stem Cell · PMID 29100015Open reference}6

• Synapse formation: Refine neuronal connections during development

• Axon guidance: Participate in neural circuit assembly

• Myelination support: Facilitate oligodendrocyte maturation

• Neuronal survival: Provide trophic support to neurons

Species Comparison

iPSC-microglia enable human-specific studies:

• Human microglia express unique genes not conserved in rodents

• Species-specific disease mechanisms can be identified

• Translational relevance improved over mouse models

Quality Control and Standardization

Essential Quality Metrics

Reproducibility Considerations

• iPSC line variability affects microglia phenotype

• Defined media formulations improve consistency

• Single-cell sequencing validates homogeneity

• Functional assays confirm reproducibility

Clinical Translation Potential

Autologous Transplantation

Patient-specific iPSC-microglia offer therapeutic potential:

• Immune compatibility: Reduced rejection risk

• Disease-specific: Correct patient mutations

• Personalized medicine: Tailored treatment approaches

Allogeneic Banking

HLA-typed iPSC lines enable “off-the-shelf” therapies:

• HLA-matched donor lines

• Reduced immune complications

• Scalable manufacturing

See Also

• Microglia

• Disease-Associated Microglia

• Neuroinflammation

• Alzheimer’s Disease

• Parkinson’s Disease

• APOE Gene

• TREM2 Gene

Therapeutic Applications

Drug Screening

iPSC-microglia enable high-throughput screening:

• Anti-inflammatory drugs**: Test compounds for microglial modulation

• Phagocytosis enhancers**: Identify agents that boost Aβ clearance

• Neuroprotective agents**: Screen for microglial neurotoxicity reduction

• Personalized screening**: Patient-specific drug responses

Cell Replacement Therapy

Autologous iPSC-derived microglia transplantation:

• Advantages: Immune-matched, disease-specific

• Challenges**: Survival, integration, functional maturation

• Clinical potential**: Treatment of AD, PD, ALS

Co-culture Systems

iPSC-microglia in advanced culture models:

Advantages and Limitations

Advantages

1. Human relevance: Species-specific biology, disease genetics

2. Patient-specific: Model individual genetic backgrounds

3. Disease modeling: Capture disease-relevant phenotypes

4. Scalability: Unlimited cell production

5. Ethical alternative: Avoid fetal tissue use

6. Personalized medicine: Individual drug screening

Limitations

1. Immaturity: Often more similar to fetal than adult microglia

2. Incomplete maturation: May lack full adult phenotype

3. Variability: Line-to-line differences

4. Cost: Expensive and time-intensive

5. Standardization: Lack of universal protocols

Future Directions and Emerging Applications

Gene Editing Approaches

The combination of iPSC technology with CRISPR-Cas9 gene editing has opened new avenues for mechanistic studies:

• Isogenic lines: Generate isogenic controls by correcting disease mutations or introducing risk alleles

• Knockout studies: Systematically investigate AD risk genes including TREM2, CD33, and APOE

• Allele-specific targeting: Distinguish effects of APOE3 versus APOE4 through precise gene editing

3D Bioprinting

Emerging bioprinting technologies enable precise spatial patterning of microglia within brain-like structures:

• Vascularized constructs: Create vascular networks to model BBB interactions

• Layer-specific assembly: Position different neuronal and glial cell types to mimic brain architecture

• Disease-on-a-chip: Integrate multiple organ-on-chip systems for comprehensive disease modeling

Clinical Translation

iPSC-derived microglia hold promise for clinical applications:

• Autologous transplantation: Patient-derived cells could be expanded and reintroduced

• Allogeneic banking: HLA-matched iPSC lines provide off-the-shelf cell products

• Gene-corrected cells: Combine gene therapy with cell replacement for monogenic diseases